DR. DONALD A. BERRY JOINS THE OTRACES' SCIENTIFIC ADVISORY BOARD TO ADD HIS EXPERTISE TO THE ADVANCEMENT OF BLOOD-BASED EARLY CANCER DETECTION

SYKESVILLE, MD --- 06/10/19

OTraces, Inc. is pleased to announce that Donald A. Berry, PhD has joined our Scientific Advisory Board. Dr. Berry is Professor of Biostatistics and Founding Chair of the Division of Quantitative Sciences at The University of Texas MD Anderson Cancer Center, as well as Founder of Berry Consultants, LLC ---- a statistical consulting firm that specializes in the Bayesian approach to medical statistics, which is radically changing the way clinical research is done in the medical device and drug industry.

Dr. Berry has extensive cancer research and policy experience and is an opinion leader in Bayesian biostatistics and adaptive clinical trial design. He long championed adaptive trials in clinical research and worked closely with the FDA Center for Devices and Radiological Health to set rigorous scientific and quality standards for a Bayesian approach, which led to adaptive designs gaining favor with both U.S. and international regulatory agencies.

Dr. Berry serves on the Scientific Advisory Board of other companies in cancer molecular diagnostics and, with OTraces, he sees particular promise for the application o**f** Bayesian methods in early cancer detection and the exploration of biomarkers that may signal the onset of tumor formation --- especially for non-small cell lung cancer (NSCLC) where OTraces' earlier pre-validation studies suggest high potential.

> OTraces' CEO and Founder, Keith Lingenfelter, has stated that *"the appointment of Professor Berry to our board is strategically important in the advancement of our patent-pending software technology platform for the detection of minimal residual disease in a routine physical examination, and for diagnosing disease progression and immune status non-invasively and in real time"*.

About OTraces

- OTraces has developed and filed extensive patents on math-, physics- and artificial intelligence-based cancer blood test software technology that can boost the accuracy of proteomic and other tests to superior levels and can detect and measure cytokine activity in the tumor microenvironment (TME) and thereby achieve real time diagnosis of tumor progression and immune status in vitro and without biopsy. This software is compatible with instrument and lab procedures already in common use across the globe, and is scalable for high-volume LDT and screening applications to facilitate commercialization, especially for LDT tests not requiring regulatory approval to launch. The OTraces technology offers superior active surveillance and screening test economics relative to ctDNA and other known methods, and has been clinically validated in blinded trials for both breast and prostate cancer at leading institutions.
-
- OTraces is seeking research partnerships and/or potentially revenue-sharing collaborations with established companies in the molecular diagnostics field interested in commercialization of this promising approach to cancer detection and diagnosis, in U.S., China and other world markets.

Investor Relations:
Keith Lingenfelter, CEO and Chairman OTraces Inc.
keith.lingenfelter@otraces.com +01-301-529 3824 cell/txt

Media Relations:
Nancy Rose Senich, nancy@rose4results.com +01-202-262-6996 cell/txt